Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive.

Pfizer (NYSE: PFE) has been around for over 175 years, but it became a true household name during the COVID-19 pandemic as one of the main vaccine suppliers. That led to its stock price and revenue ...

Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success.

Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical ...

Pfizer shares are trading in the mid-$20s as investors grapple with a critical question: is this battered pharmaceutical giant destined to remain stuck in neutral, or does its aggressive push into ...

Pfizer's post-pandemic revenue decline is temporary; new launches like Abrysvo and Adcetris, plus Seagen integration, position it for a 2025 turnaround. Valuation is compelling: Pfizer trades at deep ...

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

Pfizer’s commitment to returning capital to shareholders is evident in its current annual dividend of $1.72 per share. This translates to a quarterly payment of $0.43 per share. As of May 22, 2025, ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...